Incretin-based therapies for the failing heart

Published

Journal Article (Review)

© 2016 Wolters Kluwer Health, Inc. All rights reserved. The gut incretin hormone, glucagon-like peptide 1 (GLP-1), regulates islet hormone secretion, circulating glucose levels, and body weight, making it an attractive agent for the treatment of type 2 diabetes. As cardiovascular disease represents the leading cause of death in patients with diabetes, it is important to understand how GLP-1-based drugs impact the cardiovascular system. Here, we review recent advances in our understanding of two incretin-based drug classes, GLP-1 receptor agonists and dipeptidyl peptidase 4 inhibitors, specifically in the context of heart failure. In addition to illustrating how these therapies influence cardiac signaling processes, we describe the cardioprotective mechanisms identified in preclinical studies, while reviewing the clinical data from studies in patients with type 2 diabetes. We end by speculating why observations made in preclinical studies are not necessarily reflected in a clinically relevant patient population

Full Text

Duke Authors

Cited Authors

  • Ussher, JR; Campbell, JE

Published Date

  • January 1, 2016

Published In

Volume / Issue

  • 5 / 3

Start / End Page

  • 86 - 92

Electronic International Standard Serial Number (EISSN)

  • 2162-688X

Digital Object Identifier (DOI)

  • 10.1097/XCE.0000000000000086

Citation Source

  • Scopus